AMA Calls for ICD-10 Grace Period, MU Changes

June 9, 2015
The American Medical Association (AMA) is seeking a two-year ICD-10 grace period for physicians to avoid financial penalties to facilitate a smoother transition to the new coding set, and is also requesting that the feds fix meaningful use before moving on to Stage 3.

The American Medical Association (AMA) is seeking a two-year ICD-10 grace period for physicians to avoid financial penalties to facilitate a smoother transition to the new coding set, and is also requesting that the feds fix meaningful use before moving on to Stage 3.

Regarding ICD-10, physicians at the 2015 AMA Annual Meeting passed policy calling on the Centers for Medicare & Medicaid Services (CMS) to wave penalties for errors, mistakes or malfunctions in the system for two years directly following implementation. The policy stipulates that CMS should not withhold physician payments based on coding mistakes, “providing for a true transition, where physicians and their offices can work with ICD-10.”

This is in line with two recent bills introduced into the U.S. House of Representatives.  The first legislation, the Increasing Clarity for Doctors by Transitioning Effectively Now Act (ICD-TEN Act) introduced in May, would “require the Secretary of Health and Human Services (HHS) to provide for transparent testing to assess the transition under the Medicare fee-for-service claims processing system from the ICD-9 to the ICD-10 standard, and for other purposes,” according to the bill, which was presented by Rep. Diane Black (R-TN).

The more recent legislation, the Protecting Patients and Physicians Against Coding Act of 2015, was introduced by Representative Gary Palmer (R-AL-6) on June 4. This bill, H.R.2652, would create a two-year grace period where healthcare providers’ ICD-10-based claims submitted to Medicare and Medicaid would not be denied due to coding errors. Implementing this grace period would ensure physicians are not negatively impacted while ICD-10 is “fully implemented within the healthcare system,” according to a letter sent by Palmer to fellow Congressmen asking for their support of the bill.

“The bottom line is that ICD-10 will significantly overwhelm physician practices with a 400 percent increase in the number of codes physicians must use for diagnosis, which will take time away from the valuable one-on-one patient-physician interface that is the hallmark of taking the best care of patients,” Russell W.H. Kridel, M.D., member of the AMA Board of Trustees, said in a statement. “We continue to press both Congress and the administration to take necessary steps to avoid widespread disruption to physician practices created by this overly complex and burdensome mandate. Coding and billing protocols should never get in the way of patients receiving high quality care.”

What’s more, AMA recently told CMS that it thinks the agency should stop and assess the meaningful use program before moving forward with Stage 3. According to AMA, “The notoriously burdensome program could undergo changes that will make it easier for physicians to achieve success through 2017. However, it will take time for those changes to take effect, which is one of the reasons the AMA is urging CMS to assess the impact of the proposed changes before implementing Stage 3 in 2018.”

If CMS does indeed go forward with Stage 3, AMA recommends several changes that it thinks need to be made, including:

  • Making 2017 a transitional year to alleviate many of the concerns both vendors and providers have regarding program updates, system changes and reengineering workflows
  • Implementing a reporting period that is less than a full year, to accommodate many unforeseen system disruptions that can occur outside the physician’s control
  • Consulting physicians and vendors before removing or adding measures
  • Heavily modifying the proposed objectives to align with the needs of medical specialists
  • Allowing quality measures reported to clinical registries to count for meaningful use quality reporting requirements

The proposed Stage 3 rule was released in March, and late last month, various healthcare advocacy groups and other stakeholders questioned the logic behind some of the components of the rule.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1